Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991456 · ClinicalTrials.gov registry record · Phase 2
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02991456 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 48 participants.
The verdict
NCT02991456, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT) and temozolomide (TMZ) therapy. This is a randomized phase 2 trial of rolapitant plus ondansetron vs. ondansetron monotherapy for the prevention of chemo-radiation induced nausea and vomiting in primary MG subjects receiving RT and concomitant multi-dose TMZ.
Interventions
- DRUG Ondansetron
- DRUG Rolapitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2022-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02991456
The ClinicalTrials.gov registry entry for NCT02991456 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ondansetron is the first listed.
NCT02991456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02991456 about?
NCT02991456 is a clinical study titled "Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide". The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT) and temozolomide (TMZ) therapy. This is a randomized phase 2 trial of ...
What is the current status of trial NCT02991456?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-10-09. Estimated completion is 2022-06-20.
What interventions are being tested in trial NCT02991456?
The interventions under investigation include: Ondansetron (DRUG), Rolapitant (DRUG).
Who is sponsoring clinical trial NCT02991456?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.